Lepzacitinib
Lepzacitinib is a selective small-molecule inhibitor targeting JAK1 and JAK3, developed for research into atopic dermatitis and inflammatory skin conditions. It is utilized in both in vitro and in vivo studies to investigate mechanisms of JAK-STAT pathway inhibition and its role in modulating immune-mediated inflammation.
Product Specifications
CAS Number
2321488-47-3
Product Name Alternative
ATI1777, ATI-1777
Field of Research
Cardiovascular Research, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology
Purity
99.85% (May vary between batches)
Solubility
DMSO:80 mg/mL (225.1 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (9.29 mM)
Smiles
N (C1=C2C (=NC=C1C (OCC) =O) NC=C2) [C@H]3CN (C (CC#N) =O) CCC3
Molecular Formula
C18H21N5O3
Molecular Weight
355.39
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E-CL-H1005-01 24 Tests
Human NFE2L2 (Nuclear Factor, Erythroid Derived 2, Like 2) CLIA Kit
Sign In for Pricing
View Details E-CL-H1005-02 48 Tests
Human NFE2L2 (Nuclear Factor, Erythroid Derived 2, Like 2) CLIA Kit
Sign In for Pricing
View Details E-CL-H1005-03 96 Tests
Human NFE2L2 (Nuclear Factor, Erythroid Derived 2, Like 2) CLIA Kit
Sign In for Pricing
View Details 